Pallas Capital Advisors LLC Has $8.02 Million Holdings in Axsome Therapeutics, Inc. $AXSM

Pallas Capital Advisors LLC lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 11.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,909 shares of the company’s stock after purchasing an additional 4,465 shares during the quarter. Pallas Capital Advisors LLC owned 0.09% of Axsome Therapeutics worth $8,020,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after buying an additional 235,626 shares during the last quarter. Stanley Laman Group Ltd. bought a new position in shares of Axsome Therapeutics in the 3rd quarter valued at about $2,125,000. Aberdeen Group plc increased its position in shares of Axsome Therapeutics by 15.5% in the third quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock valued at $11,495,000 after acquiring an additional 12,732 shares during the last quarter. TD Asset Management Inc increased its position in shares of Axsome Therapeutics by 107.7% in the third quarter. TD Asset Management Inc now owns 44,192 shares of the company’s stock valued at $5,367,000 after acquiring an additional 22,914 shares during the last quarter. Finally, Swiss National Bank raised its holdings in Axsome Therapeutics by 6.9% during the second quarter. Swiss National Bank now owns 65,200 shares of the company’s stock worth $6,806,000 after acquiring an additional 4,200 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Down 4.8%

Axsome Therapeutics stock opened at $156.35 on Friday. The company’s 50-day moving average price is $173.13 and its two-hundred day moving average price is $152.00. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. The stock has a market cap of $8.00 billion, a P/E ratio of -42.37 and a beta of 0.43. Axsome Therapeutics, Inc. has a twelve month low of $86.99 and a twelve month high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The company had revenue of $196.00 million during the quarter, compared to analysts’ expectations of $191.33 million. The company’s quarterly revenue was up 65.0% on a year-over-year basis. As a group, analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, insider Ari Maizel sold 7,500 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total transaction of $1,383,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Nick Pizzie sold 12,000 shares of Axsome Therapeutics stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total value of $2,255,040.00. Following the sale, the chief financial officer directly owned 42,588 shares of the company’s stock, valued at $8,003,136.96. This represents a 21.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 289,279 shares of company stock worth $49,496,963 in the last 90 days. Company insiders own 22.30% of the company’s stock.

Analyst Ratings Changes

AXSM has been the subject of several recent research reports. Wells Fargo & Company increased their price target on Axsome Therapeutics from $193.00 to $202.00 and gave the company an “overweight” rating in a research report on Tuesday, February 24th. Leerink Partners upped their price objective on Axsome Therapeutics from $150.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. Needham & Company LLC reissued a “buy” rating and issued a $225.00 price objective on shares of Axsome Therapeutics in a report on Monday, February 23rd. UBS Group raised their target price on shares of Axsome Therapeutics from $248.00 to $251.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Finally, Guggenheim boosted their target price on shares of Axsome Therapeutics from $220.00 to $245.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $217.59.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.